Alnylam Pharmaceuticals, Inc. (ALNY)
$224.47+0.29%Close
SELLRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $30.0B
- Beta
- 0.27
- P/E (TTM)
- 36.80
- Short % float
- 5.80%
- Days to cover
- 6.5
- SI change
- +7.2%
- 1W
- +0.03%
- 1M
- -5.79%
- vs SPY 1W
- +1.01%
- vs SPY 1M
- -7.66%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 47
- VALUE
- 9
- GROWTH
- 61
- GARP
- 57
- TYPE
- Growth Compounder (blended)
Composite of Value · Growth · GARP
ROIC56.2%
REV YoY-
ROE93.6%
EPS YoY-
ROA14.5%
GROSS80
OP21
NET17
[VALUATION]
P/E TTM36.80
P/E FWD25.27
SECTOR PE20.48
INDUSTRY PE13.99
P/B22.09
P/FCF-
EV/EBITDA25.72
EV/EBIT-
PEG1.49
FCF YIELD-
RISK
INT COV-
D/E93.60
ALTMAN Z-
CURR RATIO3.05
ND/EBITDA-
BETA0.27
Company news
FAQ
- What is LOPJLB’s current signal on ALNY?
- LOPJLB’s latest quantitative signal on Alnylam Pharmaceuticals, Inc. (ALNY) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is ALNY in?
- Alnylam Pharmaceuticals, Inc. (ALNY) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Alnylam Pharmaceuticals, Inc. (ALNY) do?
- Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepat…